Pulmatrix, Inc. 4
4 · Pulmatrix, Inc. · Filed Mar 22, 2017
Insider Transaction Report
Form 4
Pulmatrix, Inc.PULM
Hava David L.
Chief Scientific Officer
Transactions
- Exercise/Conversion
Common Stock
2017-03-22$2.21/sh+2,263$5,001→ 2,263 total - Exercise/Conversion
Stock Option (Right to Buy)
2017-03-22−2,263→ 1,292 totalExercise: $2.21Exp: 2020-02-10→ Common Stock (2,263 underlying) - Award
Stock Option (Right to Buy)
2017-03-20+75,100→ 75,100 totalExercise: $2.78Exp: 2027-03-20→ Common Stock (75,100 underlying)
Footnotes (3)
- [F1]The option vests as to 25% on March 20, 2018 and the remaining 75% vests in thirty-six (36) equal monthly installments with 2.083% vesting for each of the next thirty-six (36) months that follow March 20, 2018, subject to the terms and conditions of the Pulmatrix, Inc. Amended and Restated 2013 Employee, Director and Consultant Equity Incentive Plan.
- [F2]The option, representing the right to purchase a total of 3,555 shares of common stock, was fully vested and exercisable as of February 10, 2014.
- [F3]On March 22, 2017, the Reporting Person acquired 2,263 shares of common stock upon a partial exercise of this option. Following the exercise, the Reporting Person may acquire an additional 1,292 shares of common stock pursuant to this option.